ArticleEndocrine oncology (Bristol, England)2022

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.

Marcus Vetter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.